Medulloblastoma and ependymoma cells display increased levels of 5-carboxylcytosine and elevated TET1 expression

Ashley Ramsawook 1, Lara Lewis 1, Beth Coyle 2* and Alexey Ruzov 1*

Abstract

Background: Alteration of DNA methylation (5-methylcytosine, 5mC) patterns represents one of the causes of tumorigenesis and cancer progression. Tet proteins can oxidise 5mC to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine and 5-carboxylcytosine (5caC). Although the roles of these oxidised forms of 5mC (oxi-mCs) in cancer pathogenesis are still largely unknown, there are indications that they may be involved in the mechanisms of malignant transformation. Thus, reduction of 5hmC content represents an epigenetic hallmark of human tumours, and according to our recent report, 5caC is enriched in a proportion of breast cancers and gliomas. Nevertheless, the distribution of oxi-mCs in paediatric brain tumours has not been assessed.

Findings: Here, we analyse the global levels and spatial distribution of 5hmC and 5caC in four brain tumour cell lines derived from paediatric sonic hedgehog (SHH) pathway-activated medulloblastomas (Daoy and UW228-3) and ependymomas (BXD-1425EPN and DKFZ-EP1NS). We show that, unlike HeLa cells, the paediatric tumour cell lines possess both 5hmC and 5caC at immunochemically detectable levels and demonstrate that both modifications display high degrees of spatial overlap in the nuclei of medulloblastomas and ependymomas. Moreover, although 5hmC levels are comparable in the four brain tumour cell lines, 5caC staining intensities differ dramatically between them with highest levels of this mark in a subpopulation of DKFZ-EP1NS cells. Remarkably, the 5caC enrichment does not correlate with 5hmC levels and is not associated with alterations in thymine DNA glycosylase (TDG) expression in SHH medulloblastoma and ependymoma cell lines but corresponds to elevated levels of TET1 transcript in UW228-3 and DKFZ-EP1NS cells.

Conclusions: We demonstrate that both 5caC enrichment and elevated TET1 expression are observed in SHH medulloblastomas and ependymomas. Our results suggest that increased Tet-dependent 5mC oxidation may represent one of the epigenetic signatures of cancers with neural stem cell origin and, thus, may contribute to development of novel approaches for diagnosis and therapy of the brain tumours.

Keywords: DNA methylation, 5-hydroxymethylcytosine, 5-carboxylcytosine, Paediatric brain tumours, Medulloblastoma, Ependymoma, Immunohistochemistry

© The Author(s), 2017. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Findings

Background

Alterations of both DNA methylation (5-methylcytosine, 5mC) patterns and chromatin structure are anticipated to be of key importance for the initiation and progression of human cancer [1–3]. Genomic distribution of 5mC undergoes dramatic transformation during tumorigenesis resulting in aberrant patterns of gene expression due to hypermethylation of promoters of tumour suppressor genes and to hypomethylation of oncogene’s promoters [3, 4]. Thus, malignant transformation is determined by both de novo methylation and demethylation of specific genomic regions [4, 5].

The molecular mechanisms of active DNA demethylation were largely obscure until a number of studies demonstrated that Tet (ten-eleven translocation) proteins (Tet1/2/3) can oxidise 5mC to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) [6–8]. Remarkably, apart from their potential roles in the regulation of transcription, these oxidised forms of 5mC (oxi-mCs) may also serve as intermediates in active and passive demethylation mechanisms [9–12]. Thus, both 5fC and 5caC can be recognised and excised from DNA by thymine DNA glycosylase (TDG) followed by incorporation of non-modified cytosine into the generated abasic site by the components of base-excision repair (BER) pathway [7, 8, 11]. Despite the putative involvement of the oxi-mCs in the mechanisms of DNA demethylation, the roles of these epigenetic modifications in cancer initiation and progression are currently mostly unclear [13]. However, there is a growing body of experimental evidence suggesting that both oxi-mCs and Tet proteins are important for the processes of malignant transformation [5, 13]. Thus, it is currently widely acknowledged that depletion of 5hmC represents an epigenetic hallmark of a number of human cancers [14–17]. In addition, in our recent study, we, rather unexpectedly, found that 5caC is enriched in a proportion of breast cancers and gliomas [18].

Potential biological functions of Tet-dependent 5mC oxidation have been extensively studied in adult brain tumours during several recent years [19–21]. However, neither the oxi-mCs content nor the expression levels of Tet proteins have been assessed in paediatric brain tumours. Nevertheless, a range of tumour suppressors and other genes involved in cancer pathogenesis are aberrantly methylated in both paediatric medulloblastomas and ependymomas implying that DNA (de)methylation plays important role in initiation and/or progression of these types of cancer [22].

In the present study, we aimed to determine the global levels and nuclear distribution of oxi-mCs as well as the expression of TET1/2/3 and TDG transcripts in tumour cell lines derived from paediatric medulloblastomas and ependymomas.

Methods

Cell lines and cell culture

BXD-1425EPN [23], DKFZ-EP1NS [24] and HeLa cells were cultured in Dulbecco’s modified Eagles medium (DMEM) (Gibco, Life Technologies) supplemented with 10% foetal bovine serum and 1% penicillin/streptomycin. Daoy [25] cells were cultured in MEM/EBSS supplemented with 10% heat-inactivated foetal bovine serum, sodium pyruvate, non-essential amino acids, 2 mL glutamine, 100 g/mL streptomycin and 100 U/mL penicillin. The UW228-3 [26] cell line was cultured in DMEM/F12 supplemented with 10% heat-inactivated foetal bovine serum, 2 mL glutamine, 100 g/mL streptomycin and 100 U/mL penicillin.

Immunocytochemistry, immunohistochemistry, confocal microscopy, quantification of the signal intensities and statistical analysis

Immunocytochemistry, confocal microscopy and generation of 2.5XD intensity plots and intensity profiles were performed as previously described [27]. Anti-5hmC mouse monoclonal (Active Motif, 1:5000 dilution) and anti-5caC rabbit polyclonal (Active Motif, 1:500 dilution) primary antibodies were used for immunocytochemistry. Peroxidase-conjugated anti-rabbit secondary antibody (Dako) and the tyramide signal enhancement system (PerkinElmer, 1:200 dilution, 2 min of incubation with tyramide) were employed for 5caC detection. 5hmC was visualised using 555-conjugated secondary antibody (Alexafluor). Control staining without primary antibody produced no detectable signal. Paraffin-embedded formaldehyde-fixed 12.5 dpc murine embryonic tissue was used for 5caC/5hmC immunostaining of embryonic brain cells. For quantification of the 5hmC and 5caC signal intensities in multiple cells, mean values of the average intensities of eight intensity profiles were calculated for each cell line or, for DKFZ-EP1NS cells, for the populations of 5caC-positive and 5caC-negative cells. Statistical significance was determined by two-tailed t test after assessing the variance with F test.

Gene expression analysis

Expression of TET1/2/3 and TDG transcripts was analysed by quantitative PCR according to standard procedures. Gene expression was normalised by comparison to levels of GAPDH gene expression. The following primers were used:

TET1: CTTGTAGTAGTGAGTGG and GACATTAAGTTTAGCAATGT;
TET2: GCAGATACTTTCTTACAG and GCAATGTTATGTGCAATG;
TET3: CTGGACTGGAAGGAG and GTCCAGGAAGTTGTGTTC.
Results
To examine the global levels of oxi-mCs in paediatric brain tumours, we initially performed co-detection of 5hmC with 5caC in two sonic hedgehog (SHH) pathway-activated medulloblastoma (UW228-3 and Daoy) and two ependymoma (BXD-1425EPN and DKFZ-EP1NS) cell lines using a protocol for sensitive immunostaining of modified forms of cytosine that we previously developed and validated by mass spectrometry [27]. Unlike in HeLa cells where 5caC was undetectable by immunochemistry under our experimental conditions (Fig. 1a), we observed non-negligible levels of both 5hmC and 5caC immunostaining in all the tested medulloblastoma and ependymoma cell lines (Fig. 1b). Remarkably, the intensity of the 5caC staining differed rather extensively between the paediatric brain tumour cell lines (Fig. 1b). Moreover, whereas most of the BXD-1425EPN, UW228-3 and Daoy cells exhibited similar levels of 5caC signal, the intensity of 5caC staining varied from strong (30% of cells in culture) to undetectable (70% of cells) in DKFZ-EP1NS cells (Fig. 1c, d).

We previously characterised the dynamics of 5caC levels in mouse embryonic brain tissue and showed that this mark transiently accumulates during lineage specification of neural stem cells peaking around 12.5–13.5 days post coitum (dpc) [27]. Interestingly, we found that 5hmC and 5caC were distributed in a semi-overlapping manner in the majority of 13.5 dpc murine brain cells, which
suggested that the oxidation of 5mC to 5caC is limited to specific genomic regions in these cells [27]. Based on these results, we decided to compare the nuclear distribution of 5hmC and 5caC in paediatric brain tumours with that of the cells of the murine embryonic brain at 13.5 dpc stage. Analysis of our confocal images revealed that, unlike in the cells of mouse embryonic brain, 5hmC and 5caC display high degrees of spatial overlap in the nuclei of the medulloblastoma and ependymoma cell lines we tested (Figs. 2a–e and 3a–e). Thus, 2.5XD signal intensity profiles were virtually identical for 5hmC and 5caC in the paediatric brain tumour cell lines (Figs. 2a and 3a); and signal intensity profiles for both modifications were mimicking each other in ependymoma and medulloblastoma cells (Figs. 2b–e and 3b–e), suggesting that 5mC oxidation to 5caC occurs genome-widely in these cell lines.

Fig. 2 Nuclear localization of 5caC and 5hmC in ependymoma cell lines. a 2.5XD 5caC and 5hmC signal intensity plots of the nuclei of two DKFZ-EP1NS cells with different levels of 5caC staining and a representative BXD-1425EPN nucleus compared with 2.5XD 5caC/5hmC signal intensity plot of a representative nucleus of a 13.5 dpc mouse brain cell. Merged views and individual channels are shown. b–e Merged views of the confocal images of 5caC and 5hmC immunostaining in representative nuclei of DKFZ-EP1NS and BXD-1425EPN cells (b, d) with arrows designating nuclear regions used for generation of the signal intensity profiles shown in c and e.
Next, we attempted to compare the intensities of 5hmC and 5caC signals between the four tested paediatric brain tumour cell lines employing analysis of the individual signal intensity profiles and quantification of the staining intensities in multiple cells (Fig. 4a, b). Both approaches demonstrated that, whereas the levels of 5hmC signal were comparable between all the cell lines, 5caC signal in a subpopulation of DKFZ-EP1NS cells positive for this modification (DKFZ-EP1NS H) was significantly higher ($p < 0.01$ to $p < 0.001$) compared with other paediatric brain tumour cell lines (Fig. 4b). Importantly, the levels of 5caC immunostaining did not correlate with 5hmC signal intensity in the SHH medulloblastoma and ependymoma cell lines (Fig. 4b). To get an insight into potential molecular mechanisms for the 5caC enrichment in medulloblastoma and ependymoma cells, we examined the levels of $TET1/2$ and $TDG$ transcripts in the four paediatric brain tumour cell lines and HeLa cells. These experiments revealed that neither $TDG$ nor $TET3$ expression was substantially altering between all the five tested cell lines (Fig. 4c). In contrast, expression of $TET2$ and $TET1$ was generally higher (e.g. 2.37-fold for BXD-1425EPN and 4.14-fold for DKFZ-
EPINS cells for TET2) in the brain tumour cell lines compared with HeLa cells. However, the levels of TET1 transcript exhibited the most dramatic increase in DKFZ-EP1NS and UW228-3 cells differing from HeLa in 26- and 19-fold correspondingly (Fig. 4c). Remarkably, the elevated levels of TET1 expression in DKFZ-EP1NS and UW228-3 corresponded to strong 5caC enrichment we observed in these cells.

**Discussion**

In a recently published review of TET1 functions in cancer, the authors came to conclusion that this protein has
a dual role in tumorigenesis [5]. Thus, according to a number of studies, TET1 expression is decreased in different types of malignant tissue [16, 28, 29]. Moreover, suppression of TET1 expression was reported to be associated with facilitated cell invasion and metastasis [30, 31] and even to play a critical role in KRAS-induced tumour transformation [32]. Contrasting with these reports, there is experimental evidence that TET1 acts as an oncogene in MLL-rearranged leukaemia and breast tumour malignancies [33, 34]. In this context, our observation that the levels of TET1 transcript are elevated in medulloblastoma and ependymoma cells may imply that this protein is involved in pathogenesis of the paediatric brain tumours via demethylation of the regulatory elements of the oncogenes promoting initiation and/or progression of these types of cancer.

Medulloblastoma and ependymoma represent the two most common forms of malignant paediatric brain tumours. Both tumour types have recently been categorised into clinically relevant molecular subgroups [35, 36], which can be recapitulated by methylation analyses supporting the hypothesis that epigenetic drivers may play a key role in pathogenesis of these tumour types [37, 38]. Thus, the current classification of medulloblastomas include Wnt, sonic hedgehog (SHH) and group 3 and 4 subtypes [39, 40]. The pairs of cell lines used in this study represent the most aggressive subgroups of each tumour type that respond poorly to current therapeutic approaches. UW228-3 and Daoy are both SHH pathway-activated lines harbouring a mutant TP53 gene (SHH-activated, TP53 mutant) [39]. BXD-1425EPN and DKFZ-EP1NS on the other hand represent a subgroup of ependymomas that carry a C11orf95-REL A fusion oncogene which results in activation of the NF-κB signalling pathway [40]. Remarkably, TP53 function has also recently been shown to be abrogated in the majority of RELA ependymomas where it is associated with particularly poor outcome [41]. In addition, both ependymomas and SHH medulloblastomas have been demonstrated to maintain a population of stem-like cells [42, 43]. These cells express cancer stem cell and neural stem cell markers CD133 and Nestin [42, 44–46]. Highly tumorigenic and metastatic ependymoma cell line DKFZ-EP1NS, which demonstrates in vivo primary tumour recapitulation ability in orthotopic xenograft models, expresses both these stem cell markers together with CD15 and ALDH [24]. Importantly, expression of CD15 and ALDH is also a feature shared by aggressive SHH medulloblastoma cell lines UW228-3 and Daoy [24, 47]. Correspondingly, deregulation of signalling pathways important for embryonic brain development (e.g. SHH, Wnt and Notch pathways) appears to be a hallmark of both ependymomas and medulloblastomas and to play essential role in pathogenesis of these tumours [22]. Likewise, in line with anticipated significance of Tet proteins for neuro- and gliogenesis [27], the aberrantly increased TET1-dependent 5mC oxidation may represent one of the epigenetic signatures of these cancers reflecting their likely neural progenitor/stem cell origin.

Interestingly, although 5caC enrichment corresponded to remarkably high levels of TET1 mRNA in DKFZ-EP1NS and UW228-3 cell lines in our experiments, in Daoy cells, high intensities of both 5hmC and 5caC staining were paralleled by levels of TET1/2/3 and TDG transcripts comparable with those in HeLa cells where 5caC was not detectable by immunochemistry under our conditions. This suggests that either specific post-transcriptional mechanisms of regulation of TET1/2/3 expression may be operative in this cell line or oxi-mCs may be stabilised there due to certain features of DNA methyltransferases, oxi-mCs-interacting proteins and/or components of BER machinery specific for Daoy cells.

Although the presence of 5fC and 5caC in genomic DNA is often perceived as an indication of active TET-dependent DNA demethylation, a growing body of experimental evidence suggests that all the oxi-mCs may play their own specific roles in gene regulation [27, 48–50]. Thus, developmental dynamics of 5fC is different from that of 5hmC [50], and different oxi-mCs are associated with distinct sets of regulatory sequences in the genome [27, 51]. Moreover, specific groups of candidate “reader” proteins have been identified for each of the oxi-mCs using mass spectrometry-based approaches [52]. Interestingly, the lists of potential “reader” proteins for 5fC and 5caC include a number of transcription factors, chromatin remodelling proteins and histone-modifying enzymes [52]. Therefore, our data revealing the genome-wide 5caC enrichment in UW228-3, Daoy and a subpopulation of DKFZ-EP1NS cells suggest that the presence of this modification in regulatory genomic regions may not only be linked with their demethylation but also affect transcriptional activity of the corresponding genes in these cells via 5caC-dependent recruitment of transcriptional factors or chromatin modifying complexes, contributing to the malignant phenotypes of the paediatric brain tumour cell lines.

Further studies should evaluate functional significance of increased levels of TET1 and 5caC in medulloblastoma and ependymoma providing new information on the pathogenesis and potentially leading to development of novel targets for therapy of these brain tumours. In addition, UW228-3, Daoy and DKFZ-EP1NS cells may represent a suitable experimental model to study the molecular mechanisms of Tet-dependent 5mC oxidation and potential roles of oxi-mCs in transcriptional regulation.

**Abbreviations**

Tet1: Ten-eleven translocation protein 1
Acknowledgements

We thank Robert Markus (University of Nottingham) for his help with confocal imaging.

Funding

The work was supported by the MSc course in Stem Cell Technology (University of Nottingham) and BBSRC (BB/N005759/1 to AR).

Availability of data and materials

The datasets obtained and/or analysed during the current study are available from the corresponding author upon reasonable request.

Authors’ contributions

AshR and LL performed the immunostaining experiments, confocal microscopy, qPCR and statistical analysis. AR and BC conceived the study, participated in its design and coordination and drafted the manuscript together with AshR. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Received: 21 September 2016 Accepted: 19 December 2016
Published online: 13 February 2017

References

1. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415–28.
2. Godling CR, Pei D, Lu X. Cancer: pathological nuclear reprogramming? Nat Rev Cancer. 2014;14:568–73.
3. Ehrlich M, Lacey M. DNA hypomethylation and hemimethylation in cancer. Adv Exp Med Biol. 2013;754:31–56.
4. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:10–27.
5. Tian YP, Zhu YM, Sun XH, Lai MD. Multiple functions of ten-eleven translocation 1 during tumorigenesis. Chin Med J (Engl). 2016;129:7441–51.
6. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;5929:930–3.
7. He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science. 2011;334:665–9.
8. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011;334:665–9.
9. Ficz G, Hore TA, Santos F, Lee HJ, Dean W, Arand J, et al. FGF signalling induction in ESCs drives rapid genome-wide demethylation to the epigenetic ground state of pluripotency. Cell Stem Cell. 2013;13:391–9.
10. Iurlaro M, Ficz G, Oxley D, Raber EA, Bachman M, Booth MJ, et al. A screen for the tissue inhibitors of metalloproteinases. Cell Rep. 2012;2:568–79.
11. Kang ML, Abakir A, Ferjenzits K, Dudnakova T, et al. Transient accumulation of 5-carboxylcytosine indicates involvement of active demethylation in lineage specification of neural stem cells. Cell Rep. 2014;7:1353–61.
12. Ichimura N, Shinjo K, An B, Shimizu Y, Yamao K, Ohka H, Katsushima K, Hatanaka A, Tojo M, Yamamoto E, Suzuki H, Ueda M, Kondo Y. aberrant TET1 methylation closely associated with CpG island methylator phenotype in colorectal cancer. Cancer Prev Res (Phila). 2015;8:207–17.
13. Wheldon LM, Abakir A, Ferjenzits K, Dudnakova T, et al. Transient accumulation of 5-carboxylcytosine indicates involvement of active demethylation in lineage specification of neural stem cells. Cell Rep. 2014;7:1353–61.
14. Tempest PR, Stratton MR, Cooper CS. Structure of the met protein and its essential for KRAS-mediated transformation. Cell Rep. 2014;9:1827–37.
15. Hsu CH, Peng KL, Kang ML, Chen YR, Lin YM, Huang HY, Su JM, Hsu BY, Lin ST, Lin RT, Zhang YJ, Zhao XM, Su JM, Perlampia L, Dauser R, Zhang D, Liu SH, Kondo Y. Methylosome complex. Cell Stem Cell. 2013;13:391–9.
16. Golding CR, Pei D, Lu X. Cancer: pathological nuclear reprogramming? Nat Rev Cancer. 2014;14:568–73.
17. Ehrlich M, Lacey M. DNA hypomethylation and hemimethylation in cancer. Adv Exp Med Biol. 2013;754:31–56.
18. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:10–27.
19. Tian YP, Zhu YM, Sun XH, Lai MD. Multiple functions of ten-eleven translocation 1 during tumorigenesis. Chin Med J (Engl). 2016;129:7441–51.
20. Iurlaro M, Ficz G, Oxley D, Raber EA, Bachman M, Booth MJ, et al. A screen for the tissue inhibitors of metalloproteinases. Cell Rep. 2012;2:568–79.
21. Kang ML, Abakir A, Ferjenzits K, Dudnakova T, et al. Transient accumulation of 5-carboxylcytosine indicates involvement of active demethylation in lineage specification of neural stem cells. Cell Rep. 2014;7:1353–61.
22. Ichimura N, Shinjo K, An B, Shimizu Y, Yamao K, Ohka H, Katsushima K, Hatanaka A, Tojo M, Yamamoto E, Suzuki H, Ueda M, Kondo Y. aberrant TET1 methylation closely associated with CpG island methylator phenotype in colorectal cancer. Cancer Prev Res (Phila). 2015;8:207–17.
23. Wheldon LM, Abakir A, Ferjenzits K, Dudnakova T, et al. Transient accumulation of 5-carboxylcytosine indicates involvement of active demethylation in lineage specification of neural stem cells. Cell Rep. 2014;7:1353–61.
24. Tempest PR, Stratton MR, Cooper CS. Structure of the met protein and its essential for KRAS-mediated transformation. Cell Rep. 2014;9:1827–37.
25. Hsu CH, Peng KL, Kang ML, Chen YR, Lin YM, Huang HY, Su JM, Hsu BY, Lin ST, Lin RT, Zhang YJ, Zhao XM, Su JM, Perlampia L, Dauser R, Zhang D, Liu SH, Kondo Y. Methylosome complex. Cell Stem Cell. 2013;13:391–9.
26. Golding CR, Pei D, Lu X. Cancer: pathological nuclear reprogramming? Nat Rev Cancer. 2014;14:568–73.
27. Ehrlich M, Lacey M. DNA hypomethylation and hemimethylation in cancer. Adv Exp Med Biol. 2013;754:31–56.
28. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:10–27.
29. Tian YP, Zhu YM, Sun XH, Lai MD. Multiple functions of ten-eleven translocation 1 during tumorigenesis. Chin Med J (Engl). 2016;129:7441–51.
30. Iurlaro M, Ficz G, Oxley D, Raber EA, Bachman M, Booth MJ, et al. A screen for the tissue inhibitors of metalloproteinases. Cell Rep. 2012;2:568–79.
31. Kang ML, Abakir A, Ferjenzits K, Dudnakova T, et al. Transient accumulation of 5-carboxylcytosine indicates involvement of active demethylation in lineage specification of neural stem cells. Cell Rep. 2014;7:1353–61.
32. Ichimura N, Shinjo K, An B, Shimizu Y, Yamao K, Ohka H, Katsushima K, Hatanaka A, Tojo M, Yamamoto E, Suzuki H, Ueda M, Kondo Y. aberrant TET1 methylation closely associated with CpG island methylator phenotype in colorectal cancer. Cancer Prev Res (Phila). 2015;8:207–17.
33. Wheldon LM, Abakir A, Ferjenzits K, Dudnakova T, et al. Transient accumulation of 5-carboxylcytosine indicates involvement of active demethylation in lineage specification of neural stem cells. Cell Rep. 2014;7:1353–61.
34. Tempest PR, Stratton MR, Cooper CS. Structure of the met protein and its essential for KRAS-mediated transformation. Cell Rep. 2014;9:1827–37.
35. Hsu CH, Peng KL, Kang ML, Chen YR, Lin YM, Huang HY, Su JM, Hsu BY, Lin ST, Lin RT, Zhang YJ, Zhao XM, Su JM, Perlampia L, Dauser R, Zhang D, Liu SH, Kondo Y. Methylosome complex. Cell Stem Cell. 2013;13:391–9.
36. Golding CR, Pei D, Lu X. Cancer: pathological nuclear reprogramming? Nat Rev Cancer. 2014;14:568–73.
37. Ehrlich M, Lacey M. DNA hypomethylation and hemimethylation in cancer. Adv Exp Med Biol. 2013;754:31–56.
38. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:10–27.
39. Tian YP, Zhu YM, Sun XH, Lai MD. Multiple functions of ten-eleven translocation 1 during tumorigenesis. Chin Med J (Engl). 2016;129:7441–51.
Gilbertson RJ. Cross-species genomics matches driver mutations and cell compartments to model epimepla. Nature. 2016;466:52–72.

36. Taylor MD, Northcott PA, Khoroshin A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison DW, Lichter P, Gilbertson RJ, Pomeroy SL, Kool M, Pfister SM. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123:465–72.

37. Pagliar KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, Wani K, Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Rutkowski S, Pfeffer K, Bader S, Witt O, Pfister SM, Lichter P, Taylor MD, Gilbertson RJ, Ellison DW, Aldape K, Khoroshin A, Kool M, Pfister SM. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell. 2015;27:28–43.

38. Hovestadt V, Jones DT, Picelli S, Wang W, Kool M, Northcott PA, Sultan M, Stachurski K, Rybova M, Wani K, Ralser M, Sill M, Bunt J, Jäger N, Kleinheinz K, Erkek S, Weber UD, Bartholomae CC, von Kalle C, Lawrenz C, Ellis J, Koster J, Versteeg R, Milde T, Witt O, Schmidt S, Wolf S, Pietsch T, Rutkowski S, Scheurlen W, Taylor MD, Brors B, Felsberg J, Reifenberger G, Borkhardt A, Lehrach H, Wechsler-Reya RJ, Ellis R, Yaspo ML, Landgraf P, Korshunov A, Zapatka M, Radlwimmer B, Pfister SM, Lichter P. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature. 2014;510:537–41.

39. Ramsawamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, Kool M, Dufour C, Vassal G, Milde T, Witt O, von Hoff K, Pietsch T, Northcott PA, Gajjar A, Robinson GW, Padovani L, André N, Massimino M, Pizer B, Packar R, Rutkowski S, Pfister SM, Taylor MD, Pomeroy SL. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016;131:821–31.

40. Parker M, Mohankumar MA, Puchiwehwa C, Weinrich R, Dalton JD, Li Y, Lee R, Tatevossian RG, Phoenix TN, Thienverikan R, White E, Tang B, Orsme W, Gupta K, Ruch M, Chen X, Li Y, Nagahawahette P, Hedlund E, Finkelstein D, Wu G, Shurteff S, Easton J, Boggs K, Yergeau D, Vadodaria B, Muller S, Beckfort J, Gupta P, Huehner R, Ma J, Song G, Gajjar A, Merchant T, Eilert F, Smith AA, Ding L, Lu C, Ochoa K, Zhao D, Fulton RS, Fulton LL, Mardsen ER, Wilson RK, Downing JR, Green DR, Zhang J, Ellison DW, Gilbertson RJ. C11orf95–RELA fusions drive oncogenic NF-κB activity in medulloblastoma. Nature. 2014;510:542–6.

41. Tzaridis T, Milde T, Paglieri KW, Bender S, Jones DT, Müller S, Witt H, Kool M, Pfister SM, Lichter P, Schlotter M, Kulozik AE, Lichter P, Collins VP, Witt O, Kool M, Khoroshin A, Pfister SM, Witt H. Low-dose actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma. Cancer. 2016;18:115.

42. Chang CJ, Chiang CH, Song WS, Tsai SK, Woung LC, Chang CH, Jung SY, Tsai CY, Hsu CC, Lee HF, Huang CS, Yang MC, Liu JH, Lu KH. Inhibition of phosphorylated STAT3 by curcumin I enhances chemoradiosensitivity in medulloblastoma-derived cancer stem cells. Childs Nerv Syst. 2012;28:363–73.

43. Dietl S, Schwinn S, Dietl S, Riedel S, Deinlein F, Rutkowski S, von Bueren AO, Krauss J, Schweitzer T, Vincent GH, Picard D, Eyrich M, Rosenwald A, Ramsawamy V, Taylor MD, Remke M, Monoranu CM, Beilhack A, Schlegel PG, Woff M, MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and group 3-properties. BMC Cancer. 2016;16:1115.

44. Tamanaha E, Guan S, Marks K, Saleh L. Differential processing by the iron(II)/α-ketoglutarate-dependent catalytic domains of the TET enzymes is consistent with epigenetic roles for oxidized 5-methylcytosine bases. J Am Chem Soc. 2016;138:9345–8.

45. Bachman M, Urry-Lewis S, Yang X, Williams M, Murrell A, Balasubramanian S. S-Hydroxymethylcytosine is a predominantly stable DNA modification. Nat Chem. 2016;8:1049–55.

46. Bachman M, Urry-Lewis S, Yang X, Burgess HE, Iurlaro M, Reik W, Murrell A, Balasubramanian S. S-Formylcytosine can be a stable DNA modification in mammals. Nat Chem Biol. 2015;11:555–7.

47. Iurlaro M, McIntyre GR, Burgess HE, Dean W, Raiber EA, Bachman M, Beraldi D, Balasubramanian S, Reik W. In vivo genome-wide profiling reveals a tissue-specific role for S-formylcytosine. Genome Biol. 2016;17:141.

48. Song J, Pfeifer GP. Are there specific readers of oxidized 5-methylcytosine bases? Bioessays. 2016. doi: 10.1002/bies.201600126.